Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AURA NASDAQ:ENTX NASDAQ:HUMA NASDAQ:KOD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$6.80+3.8%$6.55$4.34▼$12.38$329.26M0.46166,105 shs148,610 shsENTXEntera Bio$1.82+1.1%$1.96$1.50▼$2.79$81.81M1.52286,873 shs114,234 shsHUMAHumacyte$2.48+0.4%$2.40$1.15▼$8.24$383.14M1.93.97 million shs10.02 million shsKODKodiak Sciences$7.90-3.7%$5.05$1.92▼$11.60$432.66M2.41651,270 shs416,645 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences-4.24%-4.93%+4.80%+25.24%-20.02%ENTXEntera Bio-9.09%-6.74%+1.12%-16.28%+7.14%HUMAHumacyte+11.76%+2.92%-3.89%+107.56%-68.45%KODKodiak Sciences-0.12%+24.81%+110.26%+117.51%+251.93%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAURAAura Biosciences1.9488 of 5 stars3.60.00.00.02.13.30.0ENTXEntera Bio1.943 of 5 stars3.55.00.00.00.00.80.0HUMAHumacyte1.9095 of 5 stars3.51.00.00.02.60.80.6KODKodiak Sciences3.1658 of 5 stars2.01.00.04.62.73.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAURAAura Biosciences 3.25Buy$22.00223.53% UpsideENTXEntera Bio 3.00Buy$10.00449.45% UpsideHUMAHumacyte 3.00Buy$11.71372.35% UpsideKODKodiak Sciences 2.00Hold$9.0013.92% UpsideCurrent Analyst Ratings BreakdownLatest ENTX, HUMA, KOD, and AURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.007/9/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.006/9/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.005/28/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$22.005/23/2025AURAAura BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$19.005/14/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.005/14/2025HUMAHumacyteBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $14.005/13/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAURAAura BiosciencesN/AN/AN/AN/A$3.04 per shareN/AENTXEntera Bio$180K459.55N/AN/A$0.23 per share7.91HUMAHumacyte$1.57M245.03N/AN/A($0.41) per share-6.05KODKodiak SciencesN/AN/AN/AN/A$2.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAURAAura Biosciences-$86.92M-$1.90N/AN/AN/AN/A-58.63%-49.74%8/14/2025 (Estimated)ENTXEntera Bio-$9.54M-$0.26N/AN/AN/A-4,525.11%-95.10%-82.77%8/8/2025 (Estimated)HUMAHumacyte-$148.70M-$0.69N/AN/AN/AN/AN/A-73.59%8/12/2025 (Estimated)KODKodiak Sciences-$176.21M-$3.63N/AN/AN/AN/A-115.71%-54.17%8/13/2025 (Estimated)Latest ENTX, HUMA, KOD, and AURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025AURAAura Biosciences-$0.47N/AN/AN/AN/AN/A8/13/2025Q2 2025KODKodiak Sciences-$1.01N/AN/AN/AN/AN/A8/12/2025Q2 2025HUMAHumacyte-$0.15N/AN/AN/A$0.94 millionN/A8/8/2025Q2 2025ENTXEntera Bio-$0.11-$0.06+$0.05-$0.06N/AN/A5/15/2025Q1 2025AURAAura Biosciences-$0.47-$0.55-$0.08-$0.55N/AN/A5/14/2025Q1 2025KODKodiak Sciences-$0.89-$1.09-$0.20-$1.09N/AN/A5/13/2025Q1 2025HUMAHumacyte-$0.19-$0.10+$0.09$0.28$0.46 million$0.52 million5/9/2025Q1 2025ENTXEntera Bio-$0.07-$0.06+$0.01-$0.06N/A$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAURAAura BiosciencesN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAURAAura BiosciencesN/A11.0611.06ENTXEntera BioN/A13.0713.07HUMAHumacyte0.363.683.28KODKodiak SciencesN/A4.624.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAURAAura Biosciences96.75%ENTXEntera Bio14.11%HUMAHumacyte44.71%KODKodiak Sciences89.06%Insider OwnershipCompanyInsider OwnershipAURAAura Biosciences5.40%ENTXEntera Bio10.38%HUMAHumacyte5.10%KODKodiak Sciences45.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAURAAura Biosciences5050.27 million47.55 millionNot OptionableENTXEntera Bio2045.45 million40.73 millionOptionableHUMAHumacyte150155.12 million147.21 millionOptionableKODKodiak Sciences9052.76 million28.55 millionOptionableENTX, HUMA, KOD, and AURA HeadlinesRecent News About These CompaniesKodiak Sciences (KOD) to Release Earnings on WednesdayAugust 6 at 4:54 AM | marketbeat.comKodiak Sciences Inc. (NASDAQ:KOD) Shares Bought by GSA Capital Partners LLPAugust 4, 2025 | marketbeat.comKodiak Sciences Inc. (KOD) Stock Price Today - WSJJuly 25, 2025 | wsj.comTsunami alerts for Alaska canceled after 7.3-magnitude earthquake off AleutiansJuly 18, 2025 | msn.comPart 1: Johnson recounts PTSD treatment after May breakdownJuly 17, 2025 | kodiakdailymirror.comKEnduring the heat of CaliforniaJuly 15, 2025 | kodiakdailymirror.comKPenny Stocks To Watch In July 2025July 11, 2025 | finance.yahoo.comNASDAQ:KOD Financials | Kodiak Sciences Inc - Investing.comJuly 10, 2025 | investing.comKodiak Sciences to Host Investor R&D Day on July 16, 2025July 10, 2025 | prnewswire.comPeapod Lane Capital LLC Trims Position in Kodiak Sciences Inc. (NASDAQ:KOD)July 10, 2025 | marketbeat.comKodiak Sciences (NASDAQ:KOD) Stock Price Up 5.1% - Time to Buy?July 9, 2025 | marketbeat.comKodiak Sciences Inc. Advanced Charts | KOD | Barron'sJuly 9, 2025 | barrons.comKodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society - MorningstarJune 27, 2025 | morningstar.comMKodiak Sciences to present KSI-101 highlights at the 2025 Congress of the International Ocular Inflammation Society (IOIS)June 27, 2025 | ophthalmologytimes.comOKodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation SocietyJune 25, 2025 | prnewswire.comWhy Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?June 13, 2025 | zacks.comTrump’s cuts to fisheries science have industry and conservation groups sounding alarmJune 11, 2025 | kucb.orgKAlaska Aerospace, UAF to partner on new space venturesJune 11, 2025 | kodiakdailymirror.comKRetinal Vein Occlusion Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightJune 5, 2025 | theglobeandmail.comKodiak Sciences to Present at 2025 Jefferies Global Healthcare ConferenceMay 29, 2025 | prnewswire.comKodiak Sciences’ SWOT analysis: eye disease biotech stock at crossroadsMay 29, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENTX, HUMA, KOD, and AURA Company DescriptionsAura Biosciences NASDAQ:AURA$6.80 +0.25 (+3.82%) Closing price 04:00 PM EasternExtended Trading$6.81 +0.01 (+0.15%) As of 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Entera Bio NASDAQ:ENTX$1.82 +0.02 (+1.11%) Closing price 04:00 PM EasternExtended Trading$1.84 +0.01 (+0.82%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Humacyte NASDAQ:HUMA$2.48 +0.01 (+0.40%) Closing price 04:00 PM EasternExtended Trading$2.54 +0.06 (+2.22%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Kodiak Sciences NASDAQ:KOD$7.90 -0.30 (-3.66%) Closing price 04:00 PM EasternExtended Trading$7.91 +0.01 (+0.13%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
